Effect of bisphosphonates on the progression of degenerative aortic stenosis

Echocardiography

Volumn 28, Issue 1, 2011, Pages 1-7

  Innasimuthu, Antony Leslie ^a   Katz, William E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

aortic stenosis; bisphosphonates

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID;

AGED; AORTA STENOSIS; AORTA VALVE; ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG USE; FEMALE; HEART EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; VALVULAR HEART DISEASE;

AGED; AORTIC VALVE STENOSIS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 79251526533     PISSN: 07422822     EISSN: 15408175     Source Type: Journal    
DOI: 10.1111/j.1540-8175.2010.01256.x     Document Type: Article

References (37)

1. Rajamannan NM,: Calcific aortic stenosis: An update. Nat Clin Pract Cardiovasc Med 2007; 4: 254-262.
2. Stewart BF, Siscovick D, Lind BK, et al,: Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630-634.
3. Otto CM, Lind BK, Kitzman DW, et al,: Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341: 142-147.
4. Bonow RO, Carabello B, de Leon AC, et al,: ACC/AHA guidelines for the management of patients with valvular heart disease: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Am Coll Cardiol 1998; 32: 1486-1588.
5. Cowell SJ, Newby DE, Prescott RJ, et al,; for the Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-2397.
6. Rossebo AB, Pedersen TF, Boman, et al,; for the SEAS Investigators: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-1356.
7. Chan KL, Teo K, Dumesnil JG, et al,: Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (ASTRONOMER) Trial. Circulation 2010; 121: 306-314.
8. Drake MT, Clarke BL, Khosla S,: Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc. 2008 Sep; 83 (9): 1032-1045.
9. Tintut Y, Demer LL,: Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol 2001; 12: 555-560.
10. Price PA, Faus SA, Williamson MK,: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-824.
11. Skjaerpe T, Hegrenaes L, Hatle L,: Noninvasive estimation of valve area in patients with aortic stenosis by Doppler ultrasound and two-dimensional echocardiography. Circulation 1985; 72: 810-818.
12. Doddamani S, Bello R, Friedman M, et al,: Demonstration of Left Ventricular Outflow Tract Eccentricity by Real Time 3D Echocardiography: Implications for the Determination of Aortic Valve Area. Echocardiography 2007; 24 (8): 860-866.
13. Teague SM, Heinsimer JA, Anderson JL, et al,: Quantification of aortic regurgitation utilizing continuous wave Doppler ultrasound. J Am Coll Cardiol 1986; 8: 592-599.
14. Touche T, Prasquier R, Nitenberg A, et al,: Assessment and follow-up of patients with aortic regurgitation by an updated Doppler echocardiographic measurement of the regurgitant fraction in the aortic arch. Circulation 1985; 72: 819-824.
15. Freeman RV,: Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111: 3316-3326.
16. OBrien KD,: Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002; 106: 2224-2230.
17. Helske S,: Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004; 44: 1859-1866.
18. Ghaisas NK,: Adhesion molecules in nonrheumatic aortic valve disease: Endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol 2000; 36: 2257-2262.
19. Jian B, Narula N, Li QY, et al,: Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003; 75: 457-465, 465- 456.
20. Olsson M,: Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994; 23: 1162-1170.
21. Otto CM, Kuusisto J, Reichenbach DD, et al,: Characterization of the early lesion of degenerative valvular aortic stenosis: Histological and immunohistochemical studies. Circulation 1994; 90: 844-853.
22. Rajamannan NM,: Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003; 107: 2181-2184.
23. Miller JD, Chu Y, Brooks RM, et al,: Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008; 52: 843-850.
24. Liberman M, Bassi E, Martinatti MK, et al,: Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 2008; 28: 463-470.
25. Lai CF, Seshadri V, Huang K, et al,: An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 2006; 98: 1479-1489.
26. Russell RG, Muhlbauer RC, Bisaz S, et al,: The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathryroidectomised rats. Calcif Tissue Res 1970; 6 (3): 183-196.
27. Plotkin LI, Weinstein RS, Parfitt AM, et al,: Prevention of osteocyte and osteoblast apotosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104 (10): 1363-1374.
28. Plotkin LI, Aguirre JI, Kousteni S, et al,: Bisphosphonates and estrogens inhibit osteocyte apotosis via distinct molecular mechanisms downstream of extracellular signal regulated kinase activation. J Biol Chem 2005; 280: 7317-7325.
29. Rodan GA, Fleisch HA,: Bisphosphonates: Mechanisms of action. J Clin Invest 1996; 97: 2692-2696.
30. Sato M, Grasser W, Endo N, et al,: Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-2105.
31. Duntford JE, Thompson K, Coxon FP,: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen containing bisphosphonates. J Pharmacol Exp Ther 2001; 296 (2): 235-242.
32. Chavassieux PM, Arlot ME, Reda C, et al,: Histomorphic assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475.
33. Rosenhek R, Binder T, Porenta G, et al,: Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343: 611-617.
34. Otto CM, Burwash IG, Legget ME, et al,: Prospective study of asymptomatic valvular aortic stenosis: Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95: 2262-2270.
35. Otto CM, Pearlman AS, Gardner CL,: Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J Am Coll Cardiol 1989; 13: 545-550.
36. Peter M, Hoffmann A, Parker C, et al,: Progression of aortic stenosis: Role of age and concomitant coronary artery disease. Chest 1993; 103: 1715-1719.
37. Skolnick AH, Osranek M, Formica P, et al,: Osteoporosis treatment and progression of aortic stenosis. Am J Cardiol 2009; 104 (1): 122-124.